#USA #Upsher-Smith #Maple Grove #Ophthalmic Solution #Brimonidine Tartrate

Upsher-Smith Launches New Brimonidine Tartrate Ophthalmic Solutions

Upsher-Smith Laboratories, LLC, a subsidiary of Bora Pharmaceuticals Co., Ltd., has recently unveiled two new strengths of Brimonidine Tartrate Ophthalmic Solution: 0.1% and 0.15%. This product launch is significant, as the U.S. market for these dosages has been reported to generate annual sales of around $115 million, according to IQVIA.

Product Features and Information

Both newly introduced strengths of the Brimonidine Tartrate Ophthalmic Solution have received distinct codes that indicate their therapeutic equivalence. The 0.1% solution is labeled with a Therapeutic Equivalence Code (TE) of AB, while the 0.15% solution holds a TE code of AT. The Reference Listed Drug (RLD) for these products is branded as ALPHAGAN® P. Such classifications will help healthcare providers ensure they are prescribing effective therapies to patients.

Detailed Product Specifications:

• - Brimonidine Tartrate Ophthalmic Solution 0.1%:

- NDC #0832-1435-055: 5 mL solution in a 10 mL bottle
- NDC #0832-1435-101: 10 mL solution in a 10 mL bottle
- NDC #0832-1435-151: 15 mL solution in a 15 mL bottle

• - Brimonidine Tartrate Ophthalmic Solution 0.15%:

- NDC #0832-1420-055: 5 mL solution in a 10 mL bottle
- NDC #0832-1420-101: 10 mL solution in a 10 mL bottle
- NDC #0832-1420-151: 15 mL solution in a 15 mL bottle

Both of these solutions are designed to be effective in treating various ophthalmic conditions, particularly those related to intraocular pressure management.

Commitment to Quality and Care

Upsher-Smith Laboratories prides itself on its unwavering commitment to delivering high-quality products that can significantly improve the lives of patients. Being known as a trusted pharmaceutical company in the United States, they aim to maintain a strong focus on quality, service, and the urgency of patient needs.

To address any inquiries regarding ordering, healthcare providers can easily reach Upsher-Smith at 1-800-654-2299. Additionally, for in-depth product information, prescribing information is readily available:

• - Brimonidine Tartrate Ophthalmic Solution 0.1%
• - Brimonidine Tartrate Ophthalmic Solution 0.15%

Upsher-Smith Laboratories encourages any adverse reactions to be reported through their dedicated contact number or the FDA medwatch system, ensuring that safety and efficacy remain a priority.

About Upsher-Smith

As a proud member of Bora Group, Upsher-Smith Laboratories was established with the goal of enhancing public health through sustainable growth and high-quality pharmaceuticals. The company serves a diverse clientele with both generic and branded products, complemented by robust customer service.

Bora Pharmaceuticals, established in 2007, shares a similar vision of bettering global health by optimizing product development and addressing niche markets. With a focus on R&D and sales expansion, Bora is committed to improving patients' lives in significant ways.

To learn more about Upsher-Smith and their offerings, you can visit Upsher-Smith's website.

In conclusion, the launch of these new strengths of Brimonidine Tartrate Ophthalmic Solution embodies Upsher-Smith’s dedication to providing innovative healthcare solutions and improving patient outcomes in eye care. With comprehensive resources and commitment to quality, they continue to set standards in the pharmaceutical industry.